Drug Profile
Temsirolimus - Pfizer
Alternative Names: CCI-779; Cell cycle inhibitor-779; NSC-683864; ToriselLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Johann Wolfgang Goethe Universitatsklinikum; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; National Comprehensive Cancer Network; NCIC Clinical Trials Group; Pfizer; Wyeth
- Class Antineoplastics; Macrolides
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Mantle-cell lymphoma; Renal cell carcinoma
- Phase II Acute myeloid leukaemia; Bladder cancer; Glioblastoma; Glioma; Hodgkin's disease; Non-Hodgkin's lymphoma; Thyroid cancer
- Phase I/II Follicular lymphoma; Head and neck cancer
- No development reported Colorectal cancer; Lymphoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours
- Discontinued Breast cancer; Pancreatic cancer; Soft tissue sarcoma
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in Australia (IV, Infusion)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in Canada (IV, Infusion)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in USA (IV, Infusion)